Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
- Author
- Sarah L. Kerns, Ashley Amidon Morlang, Sharon M. Lee, Derick R. Peterson, Brian Marples, Hong Zhang, Kevin Bylund, Doug Rosenzweig, William Hall, Kim De Ruyck (UGent) , Barry S. Rosenstein, Richard G. Stock, Antonio Gómez-Caamaño, Ana Vega, Paloma Sosa-Fajardo, Begoña Taboada-Valladares, Miguel E. Aguado-Barrera, Chris Parker, Liv Veldeman (UGent) , Valerie Fonteyne (UGent) , Renée Bultijnck (UGent) , Christopher J. Talbot, R. Paul Symonds, Kerstie Johnson, Tim Rattay, Adam Webb, Maarten Lambrecht, Dirk de Ruysscher, Ben Vanneste, Ananya Choudhury, Rebecca M. Elliott, Elena Sperk, Carsten Herskind, Marlon R. Veldwijk, Tiziana Rancati, Barbara Avuzzi, Riccardo Valdagni, David Azria, Marie-Pierre Farcy Jacquet, Jenny Chang-Claude, Petra Seibold, Catharine West, Michelle Janelsins, Yuhchyau Chen, Edward Messing, Gary Morrow, Erik Briers, Alison Dunning, Sara Gutiérrez-Enríquez, Hilary Stobart and Tim Ward
- Organization
- Project
- Keywords
- Radiology, Nuclear Medicine and imaging, Oncology, Hematology, PATIENTS RECEIVING RADIOTHERAPY, GENOME-WIDE ASSOCIATION, GASTROINTESTINAL TOXICITY, ACE-INHIBITORS, IMPACT, PREVALENCE, EFFICACY, STATINS
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 368.48 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8758720
- MLA
- Kerns, Sarah L., et al. “Use of Angiotensin Converting Enzyme Inhibitors Is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.” RADIOTHERAPY AND ONCOLOGY, vol. 168, 2022, pp. 75–82, doi:10.1016/j.radonc.2022.01.014.
- APA
- Kerns, S. L., Amidon Morlang, A., Lee, S. M., Peterson, D. R., Marples, B., Zhang, H., … Ward, T. (2022). Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. RADIOTHERAPY AND ONCOLOGY, 168, 75–82. https://doi.org/10.1016/j.radonc.2022.01.014
- Chicago author-date
- Kerns, Sarah L., Ashley Amidon Morlang, Sharon M. Lee, Derick R. Peterson, Brian Marples, Hong Zhang, Kevin Bylund, et al. 2022. “Use of Angiotensin Converting Enzyme Inhibitors Is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.” RADIOTHERAPY AND ONCOLOGY 168: 75–82. https://doi.org/10.1016/j.radonc.2022.01.014.
- Chicago author-date (all authors)
- Kerns, Sarah L., Ashley Amidon Morlang, Sharon M. Lee, Derick R. Peterson, Brian Marples, Hong Zhang, Kevin Bylund, Doug Rosenzweig, William Hall, Kim De Ruyck, Barry S. Rosenstein, Richard G. Stock, Antonio Gómez-Caamaño, Ana Vega, Paloma Sosa-Fajardo, Begoña Taboada-Valladares, Miguel E. Aguado-Barrera, Chris Parker, Liv Veldeman, Valerie Fonteyne, Renée Bultijnck, Christopher J. Talbot, R. Paul Symonds, Kerstie Johnson, Tim Rattay, Adam Webb, Maarten Lambrecht, Dirk de Ruysscher, Ben Vanneste, Ananya Choudhury, Rebecca M. Elliott, Elena Sperk, Carsten Herskind, Marlon R. Veldwijk, Tiziana Rancati, Barbara Avuzzi, Riccardo Valdagni, David Azria, Marie-Pierre Farcy Jacquet, Jenny Chang-Claude, Petra Seibold, Catharine West, Michelle Janelsins, Yuhchyau Chen, Edward Messing, Gary Morrow, Erik Briers, Alison Dunning, Sara Gutiérrez-Enríquez, Hilary Stobart, and Tim Ward. 2022. “Use of Angiotensin Converting Enzyme Inhibitors Is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.” RADIOTHERAPY AND ONCOLOGY 168: 75–82. doi:10.1016/j.radonc.2022.01.014.
- Vancouver
- 1.Kerns SL, Amidon Morlang A, Lee SM, Peterson DR, Marples B, Zhang H, et al. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. RADIOTHERAPY AND ONCOLOGY. 2022;168:75–82.
- IEEE
- [1]S. L. Kerns et al., “Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer,” RADIOTHERAPY AND ONCOLOGY, vol. 168, pp. 75–82, 2022.
@article{8758720, author = {{Kerns, Sarah L. and Amidon Morlang, Ashley and Lee, Sharon M. and Peterson, Derick R. and Marples, Brian and Zhang, Hong and Bylund, Kevin and Rosenzweig, Doug and Hall, William and De Ruyck, Kim and Rosenstein, Barry S. and Stock, Richard G. and Gómez-Caamaño, Antonio and Vega, Ana and Sosa-Fajardo, Paloma and Taboada-Valladares, Begoña and Aguado-Barrera, Miguel E. and Parker, Chris and Veldeman, Liv and Fonteyne, Valerie and Bultijnck, Renée and Talbot, Christopher J. and Symonds, R. Paul and Johnson, Kerstie and Rattay, Tim and Webb, Adam and Lambrecht, Maarten and de Ruysscher, Dirk and Vanneste, Ben and Choudhury, Ananya and Elliott, Rebecca M. and Sperk, Elena and Herskind, Carsten and Veldwijk, Marlon R. and Rancati, Tiziana and Avuzzi, Barbara and Valdagni, Riccardo and Azria, David and Farcy Jacquet, Marie-Pierre and Chang-Claude, Jenny and Seibold, Petra and West, Catharine and Janelsins, Michelle and Chen, Yuhchyau and Messing, Edward and Morrow, Gary and Briers, Erik and Dunning, Alison and Gutiérrez-Enríquez, Sara and Stobart, Hilary and Ward, Tim}}, issn = {{0167-8140}}, journal = {{RADIOTHERAPY AND ONCOLOGY}}, keywords = {{Radiology,Nuclear Medicine and imaging,Oncology,Hematology,PATIENTS RECEIVING RADIOTHERAPY,GENOME-WIDE ASSOCIATION,GASTROINTESTINAL TOXICITY,ACE-INHIBITORS,IMPACT,PREVALENCE,EFFICACY,STATINS}}, language = {{eng}}, pages = {{75--82}}, title = {{Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer}}, url = {{http://doi.org/10.1016/j.radonc.2022.01.014}}, volume = {{168}}, year = {{2022}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: